Abstract The development of Bcr‐Abl tyrosine kinase inhibitors has dramatically changed
the prognosis of patients with newly diagnosed chronic myeloid leukemia (CML). Standard …

The authors used cancer registry data to assess the incidence rate of second primary
cancers among chronic myeloid leukemia (CML) patients and the long-term survival of CML …

В работе представлена история описания хронического миелолейкоза, изучения его
клинических особенностей, патогенеза и развития терапии. Приводятся результаты …

Introduction Imatinib mesylate, a selective Bcr-Abl tyrosine kinase inhibitor, has proved to be
most effective therapy of Philadelphia chromosome-positive chronic myelogenous leukemia …

The introduction of targeted therapy has revolutionized the treatment of chronic myeloid
leukemia (CML). The pivotal role of the Philadelphia chromosome, resulting from the …

Background/Aim. Imatinib mesylate, a tyrosine kinase inhibitor with specific activity against
the breakpoint cluster region-Abelson murine leukemia (BCR-ABL) tyrosine kinase has …

Imatinib is the standard firstline therapy for chronicphase chronic myelogenous leukemia
(CP CML). However, only 57% of patients in the key IRIS (International Randomized Study …

Background/Aim. Imatinib mesylate, a selective Bcr-Abl tyrosine kinase inhibitor, has
revolutionized the treatment of Bcr-Abl positive chronic myeloid leukemia and become the …

Introduction Chronic myeloid leukemia (CML) is a myelodysplastic neoplasia accounting for
around 15% of all cases of leukemia in adults. CML treatment is mainly based on tyrosine …

TERAPIJA PACIJENATA SA FILADELFIJA HROMOZOM POZITIVNOM HRONIČNOM
MIJELOIDNOM LEUKEMIJOM IMATINIB MESILATOM Page 1 16 Autori: Ivana Vidanović1 …